Four-and-a-half LIM protein 2 promotes invasive potential and epithelial-mesenchymal transition in colon cancer

Zhang, W.; Jiang, B.; Guo, Z.; Sardet, C.; Zou, B.; Lam, C. S.; Li, J.; He, M.; Lan, H. Y.; Pang, R.; Hung, I. F.; Tan, V. P.; Wang, J.; Wong, B. C.


2010-07 / vol 31 / pages 1220-9


BACKGROUND AND AIMS: Cancer invasion and metastasis may associate with the phenotype transition called epithelial-mesenchymal transition (EMT). We aim to evaluate the impact of four-and-a-half LIM protein 2 (FHL2) on EMT and invasion of colon cancer. METHODS: The functional role of FHL2 in EMT was determined by overexpression or small interfering RNA-mediated depletion of FHL2. Mechanisms of FHL2 on expression or activity of E-cadherin and beta-catenin were assessed. RESULTS: FHL2 was highly expressed in primary and metastatic colon cancer but not in normal tissues. FHL2 was critical for cancer cell adhesion to extracellular matrix, migration and invasion. FHL2 expression was stimulated by transforming growth factor (TGF)-beta1. Moreover, FHL2 acted as a potent EMT inducer by stimulating vimentin and matrix metalloproteinase-9 expressions and causing a loss of E-cadherin, whereas those alterations of EMT markers were not affected by silencing of Smad molecules (typical TGF-beta signal mediators) in FHL2 stable transfectant cells. Therefore, FHL2 induced EMT in a TGF-beta-dependent and Smad-independent manner. FHL2 downregulated E-cadherin expression and inhibited the formation of membrane-associated E-cadherin-beta-catenin complex. FHL2 also stabilized nuclear beta-catenin, resulting in enforcement of beta-catenin transactivation activity. CONCLUSION: FHL2 is a potent EMT inducer and might be an important mediator for invasion and/or metastasis of colon cancer.

Read on PubMed

bgq094 [pii] 10.1093/carcin/bgq094

1460-2180 (Electronic) 0143-3334 (Linking)


Humans; Animals; Mice; Neoplasm Metastasis; Cell Movement; Neoplasm Invasiveness; HCT116 Cells; beta Catenin/metabolism; Cadherins/analysis; Cell Adhesion; Colonic Neoplasms/*pathology; Epithelial Cells/*pathology; Homeodomain Proteins/analysis/*physiology; Mesoderm/*pathology; Muscle Proteins/analysis/*physiology; Transcription Factors/analysis/*physiology

Back to all publications